ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical

Evidence-Based GI: An ACG Publication and Podcast

ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCT

Listen now

Description

Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis,” by Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Toruner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. N Engl J Med [2019 Sep 26;381(13):1215-1226].

More Episodes

See all »

PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment?

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial,” by Noor NM...

Published 05/15/24

Multi-Target Stool DNA Test for CRC Screening: How Accurate is the New Version?

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Next-generation multitarget stool DNA test for colorectal cancer screening,” by T, Porter K, Zella J, et al. N Engl J Med. 2024; 390: 984-93.

Published 05/15/24

Linaclotide Effective for Functional Constipation in 6-17 Year Olds: First FDA-Approved Constipation Treatment for Children

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Ahmad Abu-Heija, MBBS discuss “Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial,” by Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et...

Published 05/15/24